JP2008514203A5 - - Google Patents

Download PDF

Info

Publication number
JP2008514203A5
JP2008514203A5 JP2007533758A JP2007533758A JP2008514203A5 JP 2008514203 A5 JP2008514203 A5 JP 2008514203A5 JP 2007533758 A JP2007533758 A JP 2007533758A JP 2007533758 A JP2007533758 A JP 2007533758A JP 2008514203 A5 JP2008514203 A5 JP 2008514203A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
acid molecule
filovirus
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007533758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008514203A (ja
JP5046941B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/034798 external-priority patent/WO2006037038A1/en
Publication of JP2008514203A publication Critical patent/JP2008514203A/ja
Publication of JP2008514203A5 publication Critical patent/JP2008514203A5/ja
Application granted granted Critical
Publication of JP5046941B2 publication Critical patent/JP5046941B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007533758A 2004-09-27 2005-09-27 エボラ及び他のウイルスに対する防御に最適化されたワクチン Expired - Lifetime JP5046941B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US61388304P 2004-09-27 2004-09-27
US60/613,883 2004-09-27
US67760605P 2005-05-03 2005-05-03
US60/677,606 2005-05-03
US67976705P 2005-05-10 2005-05-10
US60/679,767 2005-05-10
US70169405P 2005-07-22 2005-07-22
US60/701,694 2005-07-22
US71587405P 2005-09-09 2005-09-09
US60/715,874 2005-09-09
PCT/US2005/034798 WO2006037038A1 (en) 2004-09-27 2005-09-27 Optimized vaccines to provide protection against ebola and other viruses

Publications (3)

Publication Number Publication Date
JP2008514203A JP2008514203A (ja) 2008-05-08
JP2008514203A5 true JP2008514203A5 (cg-RX-API-DMAC7.html) 2008-11-13
JP5046941B2 JP5046941B2 (ja) 2012-10-10

Family

ID=35695786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007533758A Expired - Lifetime JP5046941B2 (ja) 2004-09-27 2005-09-27 エボラ及び他のウイルスに対する防御に最適化されたワクチン

Country Status (7)

Country Link
US (2) US8101739B2 (cg-RX-API-DMAC7.html)
EP (1) EP1797113B1 (cg-RX-API-DMAC7.html)
JP (1) JP5046941B2 (cg-RX-API-DMAC7.html)
AU (1) AU2005289439B2 (cg-RX-API-DMAC7.html)
CA (1) CA2581840C (cg-RX-API-DMAC7.html)
IL (1) IL182225A (cg-RX-API-DMAC7.html)
WO (1) WO2006037038A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
US7947286B2 (en) 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
JP5670330B2 (ja) 2008-08-07 2015-02-18 ハー マジェスティ ザ クイーン イン ライト オブ カナダ アズ リプリゼンテド バイ ザ ミニスター オブ ヘルスHER MAJESTY THE QUEEN IN RIGHTOF CANADA as represented by THE MINISTER OF HEALTH 最適化したプロモーター配列
WO2011130627A2 (en) 2010-04-16 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Chimpanzee adenoviral vector-based filovirus vaccines
KR101879892B1 (ko) * 2010-12-14 2018-08-17 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신
FI2764565T3 (fi) 2011-10-05 2023-04-24 Oned Mat Inc Piin nanorakenteen aktiivimateriaaleja litiumioniakkuihin ja niihin liittyviä prosesseja, koostumuksia, komponentteja ja laitteita
KR20220012403A (ko) * 2012-04-12 2022-02-03 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
RU2019107976A (ru) 2013-02-21 2019-08-23 Тёрнстоун Лимитед Партнершип Композиция вакцины
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CA2959105C (en) * 2014-09-03 2023-10-17 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
KR20190062617A (ko) 2014-09-03 2019-06-05 버베리안 노딕 에이/에스 면역 반응을 증대시키기 위한 방법 및 조성물
AU2015311852B2 (en) 2014-09-03 2018-12-13 Bavarian Nordic A/S Methods and compositions for inducing protective immunity against filovirus infection
CA2962849A1 (en) * 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
GB201502209D0 (en) 2015-02-10 2015-03-25 Sec Dep For Health The And Chancellor Masters And Scholars Of The University Of Oxford The And Micro Filovirus therapy
US10479825B2 (en) 2015-02-25 2019-11-19 Vanderbilt University Antibody-mediated neutralization of Marburg virus
WO2017172622A1 (en) * 2016-03-28 2017-10-05 Integrated Biotherapeutics, Inc. Pan filovirus vaccine compositions and methods of making
EP3484505A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
US10925956B2 (en) 2016-07-15 2021-02-23 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
EP3836961A1 (en) * 2018-08-13 2021-06-23 Janssen Vaccines & Prevention B.V. Stabilized filovirus glycoprotein trimers
WO2022226060A1 (en) * 2021-04-21 2022-10-27 Vanderbilt University Antibody cocktail for treatment of ebolavirus infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
WO1999032147A1 (en) * 1997-12-23 1999-07-01 The Regents Of The University Of Michigan Immunization for ebola virus infection
CA2462455C (en) * 2001-10-01 2012-07-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
AU2003232004A1 (en) * 2002-04-30 2003-11-17 The Trustees Of The University Of Pennsylvania Chimeric ebola virus envelopes and uses therefor

Similar Documents

Publication Publication Date Title
US20250235525A1 (en) Influenza vaccine
JP2023512519A5 (cg-RX-API-DMAC7.html)
US10273269B2 (en) High potency immunogenic zika virus compositions
US11103578B2 (en) Respiratory virus nucleic acid vaccines
US7528223B2 (en) Antigens encoded by alternative reading frames from pathogenic viruses
US8435535B2 (en) Fusion proteins of HIV regulatory/accessory proteins
JP2008529558A5 (cg-RX-API-DMAC7.html)
Ludwig et al. Virus-like particles—universal molecular toolboxes
JP2010500399A5 (cg-RX-API-DMAC7.html)
JP2013501038A5 (cg-RX-API-DMAC7.html)
JP2008530245A5 (cg-RX-API-DMAC7.html)
JP2013500015A5 (cg-RX-API-DMAC7.html)
JP2019519252A5 (cg-RX-API-DMAC7.html)
JP2004518631A5 (cg-RX-API-DMAC7.html)
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses
JP2006506097A5 (cg-RX-API-DMAC7.html)
US10729762B2 (en) HIV immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto
JP2004501646A5 (cg-RX-API-DMAC7.html)
WO2008154867A1 (fr) Composé immunogénique
JP2009501012A5 (cg-RX-API-DMAC7.html)
JP2024523329A5 (cg-RX-API-DMAC7.html)
CN115698295A (zh) 一种疫苗试剂和接种方法
CN103298936A (zh) 具有新型流感病毒来源的血凝素蛋白基因的重组痘苗病毒
CN114632148A (zh) 病原样抗原疫苗及其制备方法
JP5699093B2 (ja) パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物